Reference pageReimbursement

Europe Access Clocks

Explains the time gap between EMA authorization and real access or reimbursement, using country-level WAIT benchmarks and scenario controls.

EU WAIT median: 518 days
Fastest WAIT country: 52 days
Scenario coverage: 27 EU

At a glance

What to take from this page

Regulatory approval starts a second access clock.
Spravato shows how the same EU authorization can lead to different national outcomes.
WAIT averages are useful benchmarks, not product-specific forecasts.

Who this helps

General readers

Understand why an approved medicine may still be unavailable in practice.

Investors and analysts

Pressure-test market-access timing assumptions against observed reimbursement delays.

Drug developers

Plan payer work before approval instead of treating it as a post-authorization task.

Step 1

Evidence

Step 2

Approval

Step 3

Reimbursement

Step 4

Delivery

Step 5

Access

Scenario tool

Pick an EMA approval date and stress-test access timing

The table applies country-level EFPIA WAIT availability benchmarks to a generic psychedelic therapy. The dates are scenarios, not reimbursement forecasts.

EMA approval dateComplexity modifier

1.50x

EU benchmark

518 days

EFPIA EU median availability lag

Fastest shown

Germany: 78 days

20 Mar 2030

Slowest shown

Lithuania: 1289 days

13 Jul 2033

Germany

20 Mar 2030

52 benchmark days x 1.50

Austria

26 Nov 2030

219 benchmark days x 1.50

Sweden

1 Feb 2031

264 benchmark days x 1.50

Denmark

3 Feb 2031

265 benchmark days x 1.50

Cyprus

4 Apr 2031

305 benchmark days x 1.50

Finland

12 Jul 2031

371 benchmark days x 1.50

Netherlands

30 Jul 2031

383 benchmark days x 1.50

Italy

11 Aug 2031

391 benchmark days x 1.50

Country	Benchmark lag	Scenario lag	Scenario access date
Germany EU	52 days	78 days	20 Mar 2030
Austria EU	219 days	329 days	26 Nov 2030
Sweden EU	264 days	396 days	1 Feb 2031
Denmark EU	265 days	398 days	3 Feb 2031
Cyprus EU	305 days	458 days	4 Apr 2031
Finland EU	371 days	557 days	12 Jul 2031
Netherlands EU	383 days	575 days	30 Jul 2031
Italy EU	391 days	587 days	11 Aug 2031
Luxembourg EU	402 days	603 days	27 Aug 2031
Belgium EU	476 days	714 days	16 Dec 2031
Czechia EU	503 days	755 days	26 Jan 2032
Croatia EU	514 days	771 days	11 Feb 2032
Malta EU	518 days	777 days	17 Feb 2032
France EU	523 days	785 days	25 Feb 2032
Slovenia EU	550 days	825 days	5 Apr 2032
Spain EU	567 days	851 days	1 May 2032
Latvia EU	578 days	867 days	17 May 2032
Ireland EU	597 days	896 days	15 Jun 2032
Estonia EU	608 days	912 days	1 Jul 2032
Hungary EU	646 days	969 days	27 Aug 2032
Greece EU	689 days	1034 days	31 Oct 2032
Slovakia EU	705 days	1058 days	24 Nov 2032
Bulgaria EU	710 days	1065 days	1 Dec 2032
Poland EU	737 days	1106 days	11 Jan 2033
Romania EU	775 days	1163 days	9 Mar 2033
Portugal EU	795 days	1193 days	8 Apr 2033
Lithuania EU	859 days	1289 days	13 Jul 2033

Access clock values

Clock	Current value	Interpretation
EU WAIT median	518 days	Median time to availability across the EFPIA EU country set
Germany	52 days	Fastest country benchmark in the 2020-2023 WAIT set
Lithuania	859 days	Slowest EU benchmark in the scenario table
Malta	EU median fallback	EFPIA excluded Malta from the country median because too few dates were submitted

Use these values as access-clock benchmarks, not as a universal forecast for psilocybin or any other psychedelic therapy.

What the clock means

WAIT figures are access clocks after regulatory authorization, not clinical-trial timelines.

Approval starts a second pathway. Payer review, price negotiation, pathway readiness, and commissioning can add months or years before a patient can receive care.

Why access clocks can disagree

Access clocks depend on the start and stop dates. EMA authorization, national reimbursement advice, practical availability, and a negative HTA recommendation are different events.

The WAIT value is an all-medicine benchmark from the EFPIA survey, so it is useful as context rather than a direct psilocybin forecast.